IN2014CN04055A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04055A IN2014CN04055A IN4055CHN2014A IN2014CN04055A IN 2014CN04055 A IN2014CN04055 A IN 2014CN04055A IN 4055CHN2014 A IN4055CHN2014 A IN 4055CHN2014A IN 2014CN04055 A IN2014CN04055 A IN 2014CN04055A
- Authority
- IN
- India
- Prior art keywords
- proportion
- composition
- increased
- disease
- treat
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 241001657523 Coriobacteriaceae Species 0.000 abstract 1
- 241001608234 Faecalibacterium Species 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 229920001100 Polydextrose Polymers 0.000 abstract 1
- 241001430183 Veillonellaceae Species 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000835 fiber Substances 0.000 abstract 1
- 244000005709 gut microbiome Species 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229940035035 polydextrose Drugs 0.000 abstract 1
- 235000013856 polydextrose Nutrition 0.000 abstract 1
- 239000001259 polydextrose Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
- A23L7/126—Snacks or the like obtained by binding, shaping or compacting together cereal grains or cereal pieces, e.g. cereal bars
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555800P | 2011-11-04 | 2011-11-04 | |
| PCT/US2012/063008 WO2013067146A1 (en) | 2011-11-04 | 2012-11-01 | Methods and compositions for modulating gastrointestinal bacteria to promote health |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04055A true IN2014CN04055A (https=) | 2015-10-23 |
Family
ID=48192757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4055CHN2014 IN2014CN04055A (https=) | 2011-11-04 | 2012-11-01 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150209383A1 (https=) |
| EP (1) | EP2773357A4 (https=) |
| JP (1) | JP2014532710A (https=) |
| KR (1) | KR20140093252A (https=) |
| CN (1) | CN104159588A (https=) |
| AU (1) | AU2012332491A1 (https=) |
| BR (1) | BR112014010660A2 (https=) |
| CA (1) | CA2854398A1 (https=) |
| IN (1) | IN2014CN04055A (https=) |
| MX (1) | MX2014005433A (https=) |
| WO (1) | WO2013067146A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201312713D0 (en) * | 2013-03-22 | 2013-08-28 | Weaver Connie M | Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption |
| SG10201903823QA (en) | 2014-10-31 | 2019-05-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| WO2016168370A1 (en) * | 2015-04-14 | 2016-10-20 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions |
| WO2016183535A1 (en) | 2015-05-14 | 2016-11-17 | University Of Puerto Rico | Methods for restoring microbiota of newborns |
| GB201519088D0 (en) * | 2015-10-28 | 2015-12-09 | Metabogen Ab | The use of bacteria formulations |
| WO2017117142A1 (en) | 2015-12-28 | 2017-07-06 | New York University | Device and method of restoring microbiota of newborns |
| EP3199170B1 (en) * | 2016-01-26 | 2021-07-28 | FUJIFILM Corporation | Salacia for reducing the number of intestinal bacteria, food, and pharmaceutical product thereof |
| JP6301024B2 (ja) * | 2016-03-14 | 2018-03-28 | 物産フードサイエンス株式会社 | フィーカリバクテリウム属細菌増殖剤 |
| WO2018045492A1 (zh) * | 2016-09-06 | 2018-03-15 | 深圳华大基因研究院 | 长栖粪杆菌(Faecalibacterium longum)及其应用 |
| CN115919952A (zh) | 2017-06-02 | 2023-04-07 | 古德盖特公司 | 用于治疗生态失调的葡萄皮 |
| CN111372596A (zh) | 2017-08-30 | 2020-07-03 | 潘德勒姆治疗公司 | 用于治疗微生物组相关病症的方法和组合物 |
| EP3466417A1 (en) * | 2017-10-04 | 2019-04-10 | Sorbonne Université | Compounds for the prevention and treatment of glucose intolerance related conditions and obesity |
| CA3088630A1 (en) | 2017-12-15 | 2019-06-20 | Solarea Bio, Inc. | Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome |
| CN109998112B (zh) * | 2017-12-22 | 2024-05-14 | 奥地利商艾尔柏有限公司 | 红蝽杆菌纲促进肠道健康的用途 |
| US20210100831A1 (en) * | 2018-02-14 | 2021-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Polydextrose for the treatment of inflammatory diseases |
| WO2019216815A1 (en) * | 2018-05-09 | 2019-11-14 | Carbiotix Ab | Method for measuring and improving gut health |
| US11376289B2 (en) | 2018-05-31 | 2022-07-05 | Bgi Shenzhen | Composition and uses thereof |
| CA3106315A1 (en) | 2018-07-19 | 2020-01-23 | Pendulum Therapeutics, Inc. | Methods and compositions for microbial engraftment |
| CA3111795A1 (en) | 2018-09-05 | 2020-03-12 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases |
| US11980647B2 (en) | 2018-09-05 | 2024-05-14 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
| ES2763874B2 (es) * | 2018-11-30 | 2020-10-13 | Consejo Superior Investigacion | Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades |
| KR20220108765A (ko) * | 2019-10-07 | 2022-08-03 | 시올타 테라퓨틱스, 인크. | 치료용 약학 조성물 |
| KR102174095B1 (ko) * | 2019-12-11 | 2020-11-05 | 주식회사 에이치이엠 | 신규한 엔테로코커스 패시움 hem 200 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물 |
| WO2021184008A1 (en) * | 2020-03-13 | 2021-09-16 | Fitbiomics Inc. | Probiotic compositions for improving human health and athletic performance |
| JP7824034B2 (ja) * | 2020-04-16 | 2026-03-04 | サンスター株式会社 | フィーカリバクテリウム属細菌増殖用組成物、酪酸産生増加用組成物、及び腸内環境改善用組成物 |
| JP2024518270A (ja) * | 2021-05-06 | 2024-05-01 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | イノシトール、エリスリトール、又はソルビトールのうちの少なくとも１つを使用した、フィーカリバクテリウム・プラウスニッツィイの生育を増進するための組成物及び方法 |
| EP4436407A1 (en) | 2021-11-22 | 2024-10-02 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
| US20230190834A1 (en) | 2021-12-21 | 2023-06-22 | Solarea Bio, Inc. | Immunomodulatory compositions comprising microbial entities |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0394655A (ja) * | 1989-09-06 | 1991-04-19 | Otsuka Pharmaceut Co Ltd | 栄養補給用組成物 |
| JP4328473B2 (ja) * | 2001-04-09 | 2009-09-09 | 雪印乳業株式会社 | 肥満予防改善飲食品 |
| FI20020078A7 (fi) * | 2002-01-15 | 2003-07-16 | Danisco | Immuunijärjestelmän stimulointi polydextroosilla |
| JP2003334025A (ja) * | 2002-05-15 | 2003-11-25 | Toyo Shinyaku:Kk | 健康食品 |
| US7780970B2 (en) * | 2002-08-06 | 2010-08-24 | Danisco A/S | Composition |
| GB0302872D0 (en) * | 2003-02-10 | 2003-03-12 | Univ Liverpool | Treatment of inflammatory bowel disease |
| CN101677603A (zh) * | 2007-05-23 | 2010-03-24 | 泰特&莱尔组分美国公司 | 包含可缓慢消化或耐消化的寡糖组合物的可食用组合物 |
| GB0903016D0 (en) * | 2009-02-23 | 2009-04-08 | Univ Gent | Method for alleviating intestinal problems and novel bacterial strains therefor |
| BRPI1014800A8 (pt) * | 2009-05-07 | 2016-10-11 | Tate & Lyle Ingredients France SAS | "composição compreendendo alfa-(1,6) oligodextranas alfa-(1,2) ramificadas, método para preparar as referidas oligodextranas e uso das mesmas" |
-
2012
- 2012-11-01 BR BR112014010660A patent/BR112014010660A2/pt not_active IP Right Cessation
- 2012-11-01 US US14/355,963 patent/US20150209383A1/en not_active Abandoned
- 2012-11-01 AU AU2012332491A patent/AU2012332491A1/en not_active Abandoned
- 2012-11-01 CN CN201280064861.5A patent/CN104159588A/zh active Pending
- 2012-11-01 IN IN4055CHN2014 patent/IN2014CN04055A/en unknown
- 2012-11-01 KR KR1020147014663A patent/KR20140093252A/ko not_active Withdrawn
- 2012-11-01 EP EP12845672.0A patent/EP2773357A4/en not_active Withdrawn
- 2012-11-01 JP JP2014540070A patent/JP2014532710A/ja active Pending
- 2012-11-01 CA CA2854398A patent/CA2854398A1/en not_active Abandoned
- 2012-11-01 WO PCT/US2012/063008 patent/WO2013067146A1/en not_active Ceased
- 2012-11-01 MX MX2014005433A patent/MX2014005433A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2773357A4 (en) | 2015-08-26 |
| EP2773357A1 (en) | 2014-09-10 |
| JP2014532710A (ja) | 2014-12-08 |
| MX2014005433A (es) | 2014-08-22 |
| KR20140093252A (ko) | 2014-07-25 |
| AU2012332491A1 (en) | 2014-05-29 |
| WO2013067146A1 (en) | 2013-05-10 |
| US20150209383A1 (en) | 2015-07-30 |
| CA2854398A1 (en) | 2013-05-10 |
| BR112014010660A2 (pt) | 2017-05-09 |
| CN104159588A (zh) | 2014-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN04055A (https=) | ||
| Li et al. | Probiotic mixture of Lactobacillus plantarum strains improves lipid metabolism and gut microbiota structure in high fat diet-fed mice | |
| Xu et al. | Function of Akkermansia muciniphila in obesity: interactions with lipid metabolism, immune response and gut systems | |
| Zou et al. | Rice bran attenuated obesity via alleviating dyslipidemia, browning of white adipocytes and modulating gut microbiota in high-fat diet-induced obese mice | |
| Yuan et al. | Punicic acid ameliorates obesity and liver steatosis by regulating gut microbiota composition in mice | |
| Jiao et al. | Blueberry polyphenols extract as a potential prebiotic with anti-obesity effects on C57BL/6 J mice by modulating the gut microbiota | |
| Quezada et al. | Acemannan and fructans from Aloe vera (Aloe barbadensis Miller) plants as novel prebiotics | |
| Zhang et al. | Changes in intestinal microbiota of type 2 diabetes in mice in response to dietary supplementation with instant tea or matcha | |
| Shang et al. | Characterization of fecal fat composition and gut derived fecal microbiota in high-fat diet fed rats following intervention with chito-oligosaccharide and resistant starch complexes | |
| Tang et al. | The therapeutic value of bifidobacteria in cardiovascular disease | |
| Ji et al. | Fermented Rosa roxburghii Tratt juice alleviates high-fat diet-induced hyperlipidemia in rats by modulating gut microbiota and metabolites | |
| Li et al. | Crude polysaccharide extracted from Moringa oleifera leaves prevents obesity in association with modulating gut microbiota in high-fat diet-fed mice | |
| Deng et al. | Hypoglycemic effects of different molecular weight konjac glucomannans via intestinal microbiota and SCFAs mediated mechanism | |
| Zhou et al. | Gut microbiota might be a crucial factor in deciphering the metabolic benefits of perinatal genistein consumption in dams and adult female offspring | |
| Song et al. | Diet, gut microbiota, and colorectal cancer prevention: a review of potential mechanisms and promising targets for future research | |
| Panpetch et al. | Candida administration worsens cecal ligation and puncture-induced sepsis in obese mice through gut dysbiosis enhanced systemic inflammation, impact of pathogen-associated molecules from gut translocation and saturated fatty acid | |
| Deng et al. | Shatianyu (Citrus grandis L. Osbeck) flavonoids and dietary fiber in combination are more effective than individually in alleviating high-fat-diet-induced hyperlipidemia in mice by altering gut microbiota | |
| Kobyliak et al. | Comparative experimental investigation on the efficacy of mono-and multiprobiotic strains in non-alcoholic fatty liver disease prevention | |
| JP2015523362A5 (https=) | ||
| Wan et al. | The impact of dietary sn-2 palmitic triacylglycerols in combination with docosahexaenoic acid or arachidonic acid on lipid metabolism and host faecal microbiota composition in Sprague Dawley rats | |
| WO2010136900A3 (en) | Methods of using krill oil to treat risk factors for metabolic disorders and obesity | |
| Villamil et al. | Adverse effect of early-life high-fat/high-carbohydrate (“Western”) diet on bacterial community in the distal bowel of mice | |
| Aldamarany et al. | Perilla, sunflower, and tea seed oils as potential dietary supplements with anti-obesity effects by modulating the gut microbiota composition in mice fed a high-fat diet | |
| Yang et al. | Enhancing flora balance in the gastrointestinal tract of mice by lactic acid bacteria from Chinese sourdough and enzyme activities indicative of metabolism of protein, fat, and carbohydrate by the flora | |
| Liu et al. | Salidroside protects mice from high-fat diet-induced obesity by modulating the gut microbiota |